Sigmoid E-max Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY(2021)
Abstract
The use of carbapenem antibiotics to treat infections caused by Enterobacterales expressing increasingly aggressive extended-spectrum beta-lactamases (ESBLs) has contributed to the emergence of carbapenem resistance. Enmetazobactam is a novel ESBL inhibitor being developed in combination with cefepime as a carbapenem-sparing option for infections caused by ESBL-producing Enterobacterales. Cefepime-enmetazobactam checker-board MIC profiles were obtained for a challenge panel of cefepime-resistant ESBL-producing clinical isolates of Klebsiella pneumoniae. Sigmoid maximum effect (E-max) modeling described cefepime MICs as a function of enmetazobactam concentration with no bias. A concentration of 8 mu g/ml enmetazobactam proved sufficient to restore >95% of cefepime antibacterial activity in vitro against >95% of isolates tested. These results support a fixed concentration of 8 mu g/ml of enmetazobactam for MIC testing.
MoreTranslated text
Key words
enmetazobactam, cefepime, beta-lactamase inhibitor, ESBL, Enterobacterales, Klebsiella pneumoniae, beta-lactamases
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined